Indian Giant Reliance Industries Developing Niclosamide-based Drug Targeting COVID-19

Indian Giant Reliance Industries Developing Niclosamide-based Drug Targeting COVID-19

Much like Ivermectin, Niclosamide is in the anthelmintic family of drugs, and recently, Indian mega-corporation Reliance Industries Ltd. announced their plans to develop a treatment targeting COVID-19. A World Health Organization (WHO) essential medicine, Nicloasamide has been in use for over half a century and, in fact, the oral version of the drug was actually used during the 2003-04 SARS outbreak. TrialSite recently reported that a Danish biotech called UNION Therapeutics was also testing a form of Niclosamide involving trials in the UK. Of interest: can the drug stop the spread of SARS-CoV-2, the virus behind COVID-19?

Back in March of this year, TrialSite showcased clinical trials sponsored by the UK government’s Department of Health and Social Care (DHSC) known as the PROTECT-V and PROTECT-CH studies. In PROTECT-V, led by the University of Cambridge, the team will test the assess if Niclosamide is in fact a SARS-CoV-2 inhibitor. 

As reported recently in Healthworld, Reliance capitalizes on the Indian government’s move clearing Niclosamide for Phase 2 clinical trials targeting COVID-19 in adult patients. An oral medication used to treat a v...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee